Liquidia Corporation (LQDA)
LQDANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$55.21
0.0000 (0.00%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $55.21 –
- Market cap
- $4.94bn
- P/E
- 25.0
- EPS, last 4 quarters
- $2.21
- Dividend yield
- –
- Day range
- –
- 52-week range
- $22.31 to $93.61
- Average volume
- –
- Previous close
- $55.21
Analysts
8 coveringHold6 buy, 2 hold, 0 sell
Targets a year out average $62.75, +13.7% from here
Earnings
next estimate $0.1100Next report
Dec 2025
+87.5%
Mar 2026
+52.9%
Jun 2026
+5.7%
Sep 2026
+3.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $92.02m | $132.87m | $171.68m | $225.30m |
| Gross profit | $84.97m | $121.01m | $160.13m | $210.52m |
| Operating income | $19.79m | $61.50m | $85.52m | -$263.52m |
| Net income | $14.55m | $52.86m | $74.72m | -$236.33m |
Last four quarters: revenue $621.87m, margin -15.2%, free cash flow $291.15m
News
8 latest- LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesZacks · 16 hours ago
- LQDA Q3 Earnings Call Highlights Growth and Post-Settlement OutlookZacks · 19 hours ago
- Liquidia (LQDA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- Liquidia Q3 Earnings Call HighlightsMarketBeat · 1 day ago
- Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat EstimatesZacks · 1 day ago
- Zymeworks Inc. (ZYME) Misses Q3 Earnings EstimatesZacks · 2 days ago
- Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass EstimatesZacks · 6 days ago
- Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 29, 2026
The company
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT Technology. PRINT enabled the creation of YUTREPIA (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- liquidia.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.